Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease

Clinical and Experimental Nephrology

Volumn 12, Issue 4, 2008, Pages 256-263

  Tamura, Yoshifuru ^a   Kosuga, Masahiro ^a   Yamashita, Masahiro ^a   Tomioka, Satoru ^a   Sasaki, Michiko ^a   Hikita, Tomoyuki ^a   Nakajima, Hideaki ^a   Kojima, Kenichiro ^a   Uchida, Shunya ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Candesartan cilexetil; Chronic kidney disease; Hypertension; Renoprotective effects

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; CREATININE;

ADULT; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEATH; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; HEMODIALYSIS; HUMAN; KAPLAN MEIER METHOD; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION; LOG RANK TEST; MALE; MEASUREMENT; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTEINURIA; RENAL PROTECTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SURVIVAL;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHRONIC DISEASE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; TETRAZOLES;

EID: 47649103967     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-008-0040-y     Document Type: Article

References (31)

1. BM Brenner ME Cooper D de Zeeuw WF Keane WE Mitch HH Parving 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med. 345 861 9
2. EJ Lewis LG Hunsicker WR Clarke T Berl MA Pohl JB Lewis 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med. 345 851 60
3. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
4. AV Chobanian GL Bakris HR Black WC Cushman LA Green JL Izzo Jr 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension. 42 1206 52
5. Japanese Society of Hypertension Guidelines for the Management of hypertension (JSH 2004) Guidelines Subcommittee: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res. 2006;29(Suppl):S1-105.
6. GL Bakris M Siomos D Richardson I Janssen WK Bolton L Hebert 2000 ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group Kidney Int. 58 2084 92
7. MA Raebel DL McClure SR Simon KA Chan A Feldstein SE Andrade 2006 Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers Pharmacoepidemiol Drug Saf. 16 55 64
8. BF. Palmer 2003 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises Nephrol Dial Transplant. 18 1973 5
9. J Plum B Bunten R Nemeth B. Grabensee 1998 Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension J Am Soc Nephrol. 9 2223 34
10. R Toto P Shultz L Raij H Mitchell W Shaw D Ramjit 1998 Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group Hypertension. 31 684 91
11. FF Hou X Zhang GH Zhang D Xie PY Chen WR Zhang 2006 Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med. 354 131 40
12. BJ Maroni TI Steinman WE. Mitch 1985 A method for estimating nitrogen intake of patients with chronic renal failure Kidney Int. 27 58 65
13. E Imai M Horio K Nitta K Yamagata K Iseki S Hara 2007 Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease Clin Exp Nephrol. 11 41 50
14. AS Levey KU Eckardt Y Tsukamoto A Levin J Coresh J Rossert 2005 Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO) Kidney Int. 67 2089 100
15. AS Go GM Chertow D Fan CE McCulloch CY. Hsu 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med. 351 1296 305
16. A Kurtz C. Wagner 1999 Regulation of renin secretion by angiotensin II-AT1 receptors J Am Soc Nephrol. 10 Suppl 11 S162 8
17. T Wada Y Inada T Sanada M Ojima Y Shibouta M Noda 1994 Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone Eur J Pharmacol. 253 27 34
18. M Naruse A Tanabe A Sato S Takagi K Tsuchiya T Imaki 2002 Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats Hypertension. 40 28 33
19. S Klahr AS Levey GJ Beck AW Caggiula L Hunsicker JW Kusek 1994 The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med. 330 877 84
20. JC Peterson S Adler JM Burkart T Greene LA Hebert LG Hunsicker 1995 Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med. 123 754 62
21. MJ Klag PK Whelton BL Randall JD Neaton FL Brancati CE Ford 1996 Blood pressure and end-stage renal disease in men N Engl J Med. 334 13 8
22. HJ Kramer V Horacek A Backer I Vaneckova J. Heller 2004 Relative roles of nitric oxide, prostanoids and angiotensin II in the regulation of canine glomerular hemodynamics. A micropuncture study Kidney Blood Press Res. 27 10 7
23. Y Nakamura H Ono X Zhou ED. Frohlich 2001 Angiotensin type 1 receptor antagonism and ACE inhibition produce similar renoprotection in N(omega)-nitro-l>-arginine methyl ester/spontaneously hypertensive rats Hypertension. 37 1262 7
24. G De Perez Lema C De Wit CD Cohen E Nieto A Molina B Banas 2003 Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice J Pharmacol Exp Ther. 307 275 81
25. WJ Welch CS. Wilcox 2001 AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR Kidney Int. 59 1257 63
26. Z Cao F Bonnet R Candido SP Nesteroff WC Burns H Kawachi 2002 Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury J Am Soc Nephrol. 13 1773 87
27. ME Cooper P Mundel G. Boner 2002 Role of nephrin in renal disease including diabetic nephropathy Semin Nephrol. 22 393 8
28. JP Casas W Chua S Loukogeorgakis P Vallance L Smeeth AD Hingorani 2005 Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis Lancet. 366 2026 33
29. A. Ahmed 2002 Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? J Am Geriatr Soc. 50 1297 300
30. S. Hirsch 2006 Preventing end-stage renal disease: flexible strategies to overcome obstacles Curr Opin Nephrol Hypertens. 15 473 80
31. AJ Mangrum GL. Bakris 2004 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues Semin Nephrol. 24 168 75